EP #161 | Our appetite to Risk while seeking financial freedom | + News about CVS and our thoughts on Medical Properties Trust

Welcome to this episode, where we explore the details of risk management and its pivotal role in financial decisions. Starting off, we examine NVIDIA's recent earnings report and its far-reaching implications for the semiconductor industry. Our news of the week extends to CVS's strategic entry into the biosimilar arena, exploring how it could reshape its role in the healthcare sector. Our main topic revolves around the critical subject of risk and its management in the quest for financial independence. We navigate through the strategies of risk mitigation, examining portfolio diversification, asset allocation, and the balance between stability and returns. Complex concepts such as risk appetite and tolerance find their place in our discussion. Wrapping up, we answer questions from our community, providing insights into investment prospects and market dynamics. Key tickers include NVDA, CVS, MO, MPW, AD.AS, UGI, ADYEN, NEE, TROW, BATS, and DIS